Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Australian Stocks: Aquila, BHP, Pharmaxis, Rio Tinto, Woodside

Oct. 24 (Bloomberg) -- Australia’s S&P/ASX 200 Index rose 2.7 percent to 4,255 at the close of trading in Sydney as European leaders inched toward a revamped strategy to contain the region’s debt crisis.

The following were among the most active shares in the market today. Stock symbols are in parentheses after company names.

Commodity stocks: New York-traded copper futures jumped 5.4 percent, the most in two years, on Oct. 21, while the London Metal Exchange Index of prices for six metals, including copper and aluminum, gained 4.7 percent. Crude futures rose 1.6 percent on the New York Mercantile Exchange. Oil and copper futures climbed in trading today.

BHP Billiton Ltd. (BHP AU), the world’s top mining company, rose 3.2 percent to A$36.85. Rio Tinto Group (RIO AU), the world’s second-largest miner by sales, gained 4.9 percent to A$65.63.

Santos Ltd. (STO AU), Australia’s third-largest oil and gas producer, added 3.5 percent to A$12.54. Woodside Petroleum Ltd. (WPL AU), the second-biggest, advanced 3.6 percent to A$34.59.

Aquila Resources Ltd. (AQA AU) jumped 9.5 percent to A$5.67 after saying its Washpool Coal Pty unit signed a 10-year contract with QR National Ltd. (QRN AU) to transport by rail as much as 1.6 million tons a year of coal. QR National, Australia’s largest coal-train operator, advanced 2.9 percent to A$3.25.

Pharmaxis Ltd. (PXS AU) surged 50 percent to A$1.41. The Australian developer of an experimental treatment for cystic fibrosis won a recommendation from a regulatory panel of the European Medicines Agency to market Bronchitol, the company’s most-advanced drug.

To contact the reporter on this story: Shani Raja in Sydney at sraja4@bloomberg.net

To contact the editor responsible for this story: Nick Gentle at ngentle2@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.